Black Hawk Acquisition (BKHA) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Black Hawk Acquisition is the larger company by market cap ($51.2 million vs $50.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | INMB |
|---|---|---|
| Share price | $12.33 | $1.83 |
| Market cap | $51.21M | $50.79M |
| 1-day change | -5.15% | -1.61% |
| YTD return | — | +17.31% |
| 1-year return | — | -8.96% |
| 5-year return | — | -90.17% |
| P/E ratio (TTM) | 37.36 | — |
| EPS (TTM) | $0.33 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $2.60 |
| 52-week low | $11.00 | $1.09 |
| Distance from 52-week high | -6.24% | -29.62% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +282.51% |
| Average volume | 5.83K | 402.12K |
| Shares outstanding | 4.15M | 27.75M |
| Employees | — | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
BKHA vs INMB FAQ
Which is bigger, Black Hawk Acquisition or INmune Bio?
Black Hawk Acquisition (BKHA) is larger, with a market capitalization of $51.21M compared with $50.79M for INmune Bio (INMB).
Are Black Hawk Acquisition and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.